L-NAME Hydrochloride: NOS Inhibition for Vascular Research & NO Signaling

Executive Summary: L-NAME Hydrochloride (NG-nitro-L-arginine methyl ester) is a widely recognized NOS inhibitor with an IC₅₀ of ~70 μM, enabling robust suppression of nitric oxide (NO) synthesis in cellular and animal models (APExBIO, product page). It competitively inhibits multiple NOS isoforms, including eNOS, iNOS, and nNOS, and is water- and DMSO-soluble but insoluble in ethanol. L-NAME is widely used to induce hypertension and bradycardia in rats, with effects reversed by L-arginine, making it a standard tool for dissecting NO-mediated vascular mechanisms (Zhang et al. 2026, DOI). Short-term solution stability and storage at -20°C are required. Its use extends to studies on inflammation, apoptosis, and prostaglandin E2 modulation under high-glucose conditions.

Biological Rationale

Nitric oxide (NO) is an essential signaling molecule mediating vascular tone, neurotransmission, and immune responses. NO is synthesized by nitric oxide synthase (NOS) enzymes—constitutive eNOS and nNOS, and inducible iNOS—using L-arginine as substrate. Dysregulation of NO production is implicated in hypertension, endothelial dysfunction, and inflammatory pathologies (Zhang et al. 2026, DOI). Pharmacological NOS inhibitors like L-NAME Hydrochloride allow targeted, reversible suppression of NO signaling. This enables experimental modeling of vascular dysfunction, blood pressure modulation, and investigation of NO’s role in apoptosis, mRNA translation, and post-translational protein modifications (see advanced NOS inhibition strategies; this article specifically details dose-quantified benchmarks and storage best practices).

Mechanism of Action of L-NAME Hydrochloride

L-NAME Hydrochloride acts as a competitive inhibitor of NOS enzymes. It structurally mimics L-arginine but contains a nitro group, allowing it to bind the active site of NOS isoforms and block the conversion of L-arginine to NO and citrulline. This results in decreased NO synthesis and downstream effects on vascular relaxation, gene expression, and inflammation (APExBIO A7088 details). The inhibition is reversible by excess L-arginine, confirming its competitive mechanism. L-NAME is active in both cell-based and in vivo models, including rat brain and porcine aorta preparations (see translational guidance; the current article adds comparative solubility and animal dosing data).

Evidence & Benchmarks

• L-NAME Hydrochloride inhibits NOS activity in rat brain preparations with an IC₅₀ of ~70 μM (APExBIO, product page).
• In porcine aortic endothelial cells, L-NAME shows dose-dependent suppression of eNOS with confirmed reversibility by L-arginine (Zhang et al. 2026, DOI).
• Intravenous administration in rats (0.03–300 mg/kg) causes quantifiable increases in mean arterial blood pressure and bradycardia (APExBIO).
• At 1 mM in retinal cell cultures, L-NAME inhibits both NO and prostaglandin E2 production, and downregulates iNOS and COX-2 under high glucose (Zhang et al. 2026, DOI).
• Short-term stability: Solutions remain effective for experimental use when freshly prepared; recommended storage is at -20°C (APExBIO, product page).

Applications, Limits & Misconceptions

L-NAME Hydrochloride is employed in cardiovascular disease modeling, hypertension research, and mechanistic studies of endothelial function. Its ability to reversibly inhibit NO synthesis allows experimental control of vascular tone and inflammation. APExBIO’s L-NAME Hydrochloride is validated for both in vitro (cell culture) and in vivo (animal) research. For comprehensive mechanistic insights, see this article exploring vasculature-specific frontiers; the present work emphasizes validated dosing, IC₅₀ ranges, and cross-species evidence.

Common Pitfalls or Misconceptions

• L-NAME is not selective for a single NOS isoform; it inhibits eNOS, iNOS, and nNOS with similar affinity.
• Effects are reversible by L-arginine supplementation; failure to control for this confounder may invalidate results.
• It does not directly inhibit downstream NO signaling targets or compensate for non-NO-dependent vasorelaxation mechanisms.
• Long-term or high-dose use may induce systemic side effects unrelated to NO inhibition, such as renal impairment.
• It is not effective in ethanol-based solutions due to poor solubility; use water or DMSO as solvents.

Workflow Integration & Parameters

For in vitro applications, L-NAME Hydrochloride is typically used at concentrations ranging from 10 μM to 1 mM, depending on cell type and experimental design. In vivo studies in rodents employ intravenous doses from 0.03 to 300 mg/kg to modulate blood pressure and vascular responses. Prepare fresh solutions in water (≥27 mg/mL) or DMSO (≥23 mg/mL); avoid ethanol. Store as a solid at -20°C for maximum stability. Short-term solution use is advised. For troubleshooting and reproducibility strategies, see this best practices guide; this article provides updated stability and dose data.

Conclusion & Outlook

L-NAME Hydrochloride, as supplied by APExBIO, remains a gold-standard NOS inhibitor for vascular tone regulation studies, hypertension models, and mechanistic dissection of NO-dependent signaling. Its well-characterized, reversible inhibition and validated dosing benchmarks support reproducibility in both basic and translational research. Ongoing advances in NO biology, prostaglandin cross-talk, and precision cardiovascular modeling continue to expand its utility. For full product specifications and ordering, see the L-NAME Hydrochloride product page.